Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Kiungo kimehifadhiwa kwenye clipboard

HaliImekamilika

Wadhamini

The George Washington University Biostatistics Center

Washirika

National Heart, Lung, and Blood Institute (NHLBI)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

JARIBIO LA KLINIKI: NCT00135707

BioSeek: nct00135707

Maneno muhimu

Kikemikali

Preeclampsia is one of the most common complications of pregnancy and is characterized by high blood pressure and protein in the urine. This can cause problems in the second half of pregnancy for both the mother and fetus. This study of preeclampsia consists of two parts: 1) a randomized, placebo controlled, multicenter clinical trial of 10,000 low-risk nulliparous women between 9 and 16 weeks gestation and 2) an observational, cohort study of 4,000 patients between 9 and 12 weeks gestation who are also enrolled in the trial.

Subjects in both parts will receive either 1000 mg of vitamin C and 400 IU of vitamin E or matching placebo daily. The purpose of the randomized, clinical trial is to find out if high doses of vitamin C and E will reduce the risk of preeclampsia and other problems associated with the disease. The study will also evaluate the safety of antioxidant therapy for mother and infant. Patients will be seen monthly to receive their supply of study drug, to have weight and blood pressure recorded, to have urine protein measured, and to assess any side effects. At two visits, blood and urine will be collected.

The observational, cohort study will prospectively measure potential biochemical and biophysical markers that might predict preeclampsia. These patients will have additional procedures including uterine artery Doppler and blood drawn for a complete blood count (CBC).

Maelezo

A Randomized, Clinical Trial of Antioxidants to Prevent Preeclampsia:

Preeclampsia is the leading cause of maternal morbidity, as well as perinatal morbidity and mortality. Once the diagnosis has been established, therapy other than delivery has not been successful except to prolong pregnancy minimally (at some risk to mother and infant). Prevention efforts to reduce or eliminate preeclampsia are directed at the pathophysiology of the disorder prior to clinically evident preeclampsia and before irreversible changes have occurred.

This double-masked, placebo-controlled trial of 10,000 subjects is designed to evaluate the effects of antioxidant therapy in preventing serious complications associated with pregnancy-related hypertension in low risk, nulliparous women who begin treatment at 9-16 weeks gestation. The hypothesis being tested is that antioxidant therapy initiated prior to 16 weeks gestation will reduce the frequency of serious maternal and infant complications associated with pregnancy-related hypertension.

After randomization, subjects will receive either 1000 mg of vitamin C and 400 IU of vitamin E or matching placebo daily. They will be seen for monthly pill counts and to assess side effects, weight, blood pressure, and urine for protein. Blood and urine are collected at 24 and 32 weeks' gestation.

An Observational Cohort Study to Predict Preeclampsia:

A prospective, cohort study has been designed to complement the randomized, controlled, trial (RCT) and will test various biochemical and biophysical markers for ability to predict preeclampsia in 4,000 of the women who are enrolled in the RCT and are between 9 and 12 weeks gestation. These subjects will have additional procedures including a CBC and uterine artery Doppler.

Tarehe

Imethibitishwa Mwisho:	01/31/2019
Iliyowasilishwa Kwanza:	08/23/2005
Uandikishaji uliokadiriwa Uliwasilishwa:	08/23/2005
Iliyotumwa Kwanza:	08/25/2005
Sasisho la Mwisho Liliwasilishwa:	02/18/2019
Sasisho la Mwisho Lilichapishwa:	02/20/2019
Tarehe ya matokeo ya kwanza yaliyowasilishwa:	10/31/2012
Tarehe ya matokeo ya kwanza ya QC yaliyowasilishwa:	10/22/2018
Tarehe ya matokeo ya kwanza kuchapishwa:	11/19/2018
Tarehe halisi ya kuanza kwa masomo:	05/31/2003
Tarehe ya Kukamilisha Msingi iliyokadiriwa:	09/30/2008
Tarehe ya Kukamilisha Utafiti:	12/31/2008

Hali au ugonjwa

Preeclampsia

Uingiliaji / matibabu

Drug: Dietary Supplement/Vitamins

Drug: Placebo for Vitamin C and Vitamin E

Awamu

Awamu 3

Vikundi vya Arm

Mkono	Uingiliaji / matibabu
Experimental: Dietary Supplement/Vitamins 1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.	Drug: Dietary Supplement/Vitamins Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
Placebo Comparator: Placebo for Vitamin C and Vitamin E Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.	Drug: Placebo for Vitamin C and Vitamin E Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.

Vigezo vya Kustahiki

Jinsia Inastahiki Kujifunza

Female

Hupokea Wajitolea wa Afya

Ndio

Vigezo

RCT Inclusion Criteria:

- Gestational age 9 -16 weeks

- Singleton pregnancy

- Nulliparous

Observational Inclusion Criteria:

- Women randomized to the RCT

- Gestational age 9 - 12 wks

Exclusion Criteria RCT and Observational:

- BP >= 135/85

- Proteinuria

- History or current use of anti-hypertensive medication or diuretics

- Use of vitamins C > 150 mg and/or E > 75 IU per day

- Pregestational diabetes

- Current pregnancy is a result of in vitro fertilization

- Regular use of platelet active drugs or non-steroidal anti-inflammatory drugs (NSAIDS)

- Known fetal abnormalities

- Documented uterine bleeding within a week of screening

- Uterine malformations

- History of medical complications

- Illicit drug or alcohol abuse during current pregnancy

- Intent to deliver elsewhere

- Participating in another interventional study

Matokeo

Hatua za Matokeo ya Msingi

1. Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate [20 weeks through discharge following delivery]

Severe hypertension (blood pressure [BP]>= 160/110) or mild hypertension (BP>= 140/90) >= 20 weeks gestation in conjunction with one of the following: elevated liver enzymes, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, an indicated preterm birth before 32 weeks of gestation owing to hypertension-related disorders, a fetus that was small for gestational age (below 3rd percentile) adjusted for sex and race or ethnic group, fetal death after 20 weeks of gestation, or neonatal death

2. Severe Hypertension [20 weeks through discharge following delivery]

Included here are women who had severe hypertension only and those who had severe hypertension with elevated liver enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, medically indicated preterm birth, fetal-growth restriction, or fetal death after 20 weeks of gestation, or neonatal death.

3. Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels [20 weeks through discharge following delivery]

Elevated liver enzyme levels are specified as an aspartate aminotransferase level of >= 100 U per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.

4. Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia [20 weeks through discharge following delivery]

Thrombocytopenia defined as a platelet count of <100,000 per cubic millimeter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.

5. Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level [20 weeks through discharge following delivery]

Elevated serum creatinine defined as ≥1.5 mg per deciliter or 132.6 μmol per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.

6. Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure [20 weeks through discharge following delivery]

Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.

7. Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders [20 weeks through discharge following delivery]

8. Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group [20 weeks through discharge following delivery]

9. Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death [20 weeks through discharge or prior to discharge following delivery admission]

Hatua za Matokeo ya Sekondari

1. Preeclampsia (Mild, Severe, HELLP Syndrome, Eclampsia) [20 weeks through discharge following delivery]

HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count.

2. Pregnancy Associated Hypertension [20 weeks through discharge following delivery]

3. Medically Indicated Delivery Because of Hypertension [20 weeks through discharge following delivery]

4. Aspartate Aminotransferase ≥100 U/Liter [20 weeks through discharge]

5. Creatinine ≥1.5 mg/dl (133 μmol/Liter) [20 weeks through discharge]

6. Antepartum Bleeding [During pregnancy]

7. Premature Rupture of Membranes [During pregnancy]

8. Placental Abruption [During pregnancy]

9. Cesarean Delivery [Delivery]

10. Maternal Death [Delivery through hospital discharge]

11. Postpartum Pulmonary Edema [After delivery through discharge]

12. Hematocrit ≤24% With Transfusion [Delivery admission to discharge]

13. Maternal Hospital Stay [Delivery through discharge]

14. Gestational Age at Delivery [Delivery]

15. Preterm Birth [Delivery]

16. Fetal or Neonatal Death [During pregnancy or thorugh discharge]

17. Birth Weight [At birth]

18. Small for Gestational Age [At birth]

A baby whose birth weight is less than the 3rd percentile is considered to be small for gestational age (adjusted for sex and race or ethnic group)

19. Birth Weight <2500 Grams [At birth]

20. Admission to NICU [Delivery through discharge]

NICU denotes neonatal intensive care unit.

21. Respiratory Distress Syndrome [Delivery through discharge]

22. Intraventricular Hemorrhage, Grade III or IV [Delivery through discharge]

23. Sepsis [Delivery through discharge]

24. Necrotizing Enterocolitis [Delivery through discharge]

25. Retinopathy of Prematurity [Within 1 month of birth]

26. Apgar Score <=3 at 5 Minutes [At birth]

27. Neonatal Hospital Stay [Birth through discharge from hospital]